Clinical Trials Finder
Independent ClinicalTrials.gov directory
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

ClinicalTrials.gov ID: NCT07449702

Public ClinicalTrials.gov record NCT07449702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced May 18, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Study identification

NCT ID
NCT07449702
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Enrollment
80 participants

Conditions and interventions

Interventions

  • ORKA-001 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 22, 2026
Primary completion
Oct 31, 2028
Completion
Dec 31, 2028
Last update posted
Apr 21, 2026

2026 – 2029

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
11
Facility City State ZIP Site status
Oruka Therapeutics Investigative Site Los Angeles California 90045 Recruiting
Oruka Therapeutics Investigative Site San Diego California 92123 Recruiting
Oruka Therapeutics Investigative Site Santa Ana California 92701 Recruiting
Oruka Therapeutics Investigative Site Santa Monica California 90404 Recruiting
Oruka Therapeutics Investigative Site Cromwell Connecticut 06416 Recruiting
Oruka Therapeutics Investigative Site Coral Gables Florida 33134 Recruiting
Oruka Therapeutics Investigative Site Bowling Green Kentucky 42104 Recruiting
Oruka Therapeutics Investigative Site Rockville Maryland 20850 Recruiting
Oruka Therapeutics Investigative Site Detroit Michigan 48202 Recruiting
Oruka Therapeutics Investigative Site New York New York 10023 Recruiting
Oruka Therapeutics Investigative Site New York New York 10029 Recruiting
Oruka Therapeutics Investigative Site Portland Oregon 97201 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07449702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 21, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07449702 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →